Results 201 to 210 of about 854,863 (214)
Some of the next articles are maybe not open access.

Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer

Cell Reports, 2018
Amelia Shoemark   +2 more
exaly  

The cyclin-dependent kinase inhibitor p21 is required for TGF-β1-induced podocyte apoptosis

Kidney International, 2005
Jeffrey Pippin
exaly  

In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor

Kidney International, 1999
Ellis Avner, E D Avner, W E Sweeney
exaly  

CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases

Multiple Sclerosis Journal, 2020
Xavier Montalban, Dalia L Rotstein
exaly  

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

Annals of Oncology, 2004
Thierry le Chevalier   +2 more
exaly  

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

Expert Opinion on Investigational Drugs, 2000
Lloyd R Kelland
exaly  

The Pseudo Natural Product Myokinasib Is a Myosin Light Chain Kinase 1 Inhibitor with Unprecedented Chemotype

Cell Chemical Biology, 2019
George Karageorgis   +2 more
exaly  

Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours

Expert Opinion on Investigational Drugs, 2007
Anne L Thomas   +2 more
exaly  

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

European Journal of Cancer, 2012
Thierry Gil   +2 more
exaly  

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma

Annals of Oncology, 2016
Antonio Viúdez   +2 more
exaly  
medicine
pharmacology
therapeutics
previous   19  20  21  22  

Home - About - Disclaimer - Privacy